BTIG Research Analysts Give Sarepta Therapeutics (SRPT) a $190.00 Price Target
BTIG Research set a $190.00 price objective on Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued to investors on Monday morning. The firm currently has a buy rating on the biotechnology company’s stock.
SRPT has been the topic of a number of other research reports. BidaskClub cut Sarepta Therapeutics from a strong-buy rating to a buy rating in a research report on Friday, July 27th. HC Wainwright set a $267.00 target price on Sarepta Therapeutics and gave the stock a buy rating in a research report on Tuesday, September 4th. Citigroup initiated coverage on Sarepta Therapeutics in a research report on Tuesday, August 14th. They set a buy rating on the stock. Bank of America initiated coverage on Sarepta Therapeutics in a research report on Friday, September 14th. They issued a buy rating and a $199.00 price target on the stock. Finally, William Blair restated a buy rating on shares of Sarepta Therapeutics in a research report on Tuesday, June 19th. Three investment analysts have rated the stock with a hold rating, twenty-three have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $157.52.
SRPT opened at $158.80 on Monday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 9.89 and a current ratio of 10.88. Sarepta Therapeutics has a one year low of $42.97 and a one year high of $176.50. The stock has a market cap of $10.17 billion, a PE ratio of -96.66 and a beta of 1.30.
In other Sarepta Therapeutics news, SVP David T. Howton sold 50,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $136.46, for a total value of $6,823,000.00. Following the sale, the senior vice president now owns 37,967 shares of the company’s stock, valued at approximately $5,180,976.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Alexander Cumbo sold 33,782 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, July 9th. The shares were sold at an average price of $137.32, for a total value of $4,638,944.24. Following the completion of the sale, the senior vice president now directly owns 40,690 shares in the company, valued at approximately $5,587,550.80. The disclosure for this sale can be found here. Insiders own 7.90% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in SRPT. Waddell & Reed Financial Inc. purchased a new stake in Sarepta Therapeutics in the 2nd quarter valued at approximately $103,682,000. Millennium Management LLC boosted its holdings in Sarepta Therapeutics by 242.2% in the 2nd quarter. Millennium Management LLC now owns 858,407 shares of the biotechnology company’s stock valued at $113,464,000 after purchasing an additional 607,588 shares in the last quarter. Boxer Capital LLC purchased a new stake in Sarepta Therapeutics in the 2nd quarter valued at approximately $49,568,000. Macquarie Group Ltd. boosted its holdings in Sarepta Therapeutics by 444.0% in the 2nd quarter. Macquarie Group Ltd. now owns 383,093 shares of the biotechnology company’s stock valued at $50,637,000 after purchasing an additional 312,670 shares in the last quarter. Finally, RTW Investments LP boosted its holdings in Sarepta Therapeutics by 42.2% in the 2nd quarter. RTW Investments LP now owns 978,551 shares of the biotechnology company’s stock valued at $129,345,000 after purchasing an additional 290,280 shares in the last quarter. 89.99% of the stock is currently owned by institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Recommended Story: How to Invest in Marijuana Stocks
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.